Wesfarmers' API Acquisition Targets Long-Term Growth -- Market Talk
Wesfarmers' API Acquisition Targets Long-Term Growth -- Market Talk
0041 GMT - Wesfarmers' acquisition of Australian Pharmaceutical Industries makes healthcare the next growth area for the retail and industrial conglomerate, UBS says. The investment bank sees the move as part of a strategy to focus on long-term growth, with low-cost access already secured to large markets in lithium, online marketplaces and trade hardware. Wesfarmers will bring capital and skills in retail, distribution and data to the growing health, wellbeing and beauty industry, UBS says. It thinks API's membership program will be an attractive addition to Wesfarmers' existing data and digital operations. UBS maintains a neutral rating and A$62.00 target price on the stock, which is down 0.2% at A$59.92. (stuart.condie@wsj.com; @StuartLCondie)
0041GMT-瑞銀表示，Wesfarmers收購澳大利亞製藥工業公司，使醫療保健成為這家零售和工業集團的下一個增長領域。這家投行將此舉視為專注於長期增長的戰略的一部分，因為鋰、在線市場和貿易硬件領域的大型市場已經獲得了低成本的准入。瑞銀表示，西部農場主將為不斷增長的健康、福祉和美容行業帶來零售、分銷和數據方面的資金和技能。它認為API的會員計劃將是西部農民現有數據和數字業務的一個有吸引力的補充。瑞銀維持對該股的中性評級和62.00澳元的目標價，該股下跌0.2%，報59.92澳元。(stuart.Condie@wsj.com；@StuartLCondie)
譯文內容由第三人軟體翻譯。